To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

Post Category: Brain Cancer

May 21, 2024
Announcing 2024’s National HOPE Award Recipient

We are proud to present the 2024 National HOPE Award to Patrick "Paddy" O'Donnell!

Read More
April 23, 2024
tovorafenib FDA Approval for LGG

(Courtesy of ASCO FDA Alerts) tovorafenib FDA Approval for LGG On April 23, 2024, the Food and Drug Administration granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.) for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. […]

Read More
November 21, 2023
A Grateful November: Celebrating Family Caregivers

In the spirit of Thanksgiving, November becomes a canvas for expressions of gratitude. It's a time to spotlight the often-overlooked heroes among us—family caregivers. These remarkable individuals selflessly carry emotional, physical, and financial responsibilities to safeguard their loved ones on challenging health journeys. Let's take a moment to honor and celebrate these caregivers who give […]

Read More
November 9, 2023
EBCI Attends SNO 2023

The End Brain Cancer Initiative team is proud to be attending the 2023 Society for Neuro-Oncology Annual Meeting (SNO)

Read More
October 2, 2023
Oncoheroes Gains FDA Approval for Pediatric Cancer Drug Trials

In a groundbreaking development for pediatric oncology, Oncoheroes Biosciences, Inc. has received the FDA's green light to proceed with two crucial clinical trials. This milestone opens the door to exploring potential drug treatments for young cancer patients, offering newfound hope in the fight against childhood cancer. The U.S. Food and Drug Administration (FDA) recently granted […]

Read More
September 18, 2023
FDA Widens Temodar's Approval to Fight Another Brain Cancer Type

The FDA expanded use of Temodar to include two new indications for the treatment of adults with anaplastic astrocytoma.

Read More
January 27, 2023
Sonodynamic Therapy Clinical Trial

Read about this NEW Clinical Trial and review the eligibility guidelines! "The Ivy Brain Tumor Center at Barrow Neurological Institute is conducting a Phase 1/2 study of sonodynamic therapy (SDT) in patients with recurrent glioblastoma (rGBM).

Read More
January 20, 2023
New cell therapy, cancer killing vaccine

Scientists at Brigham and Women’s Hospital are harnessing a new way to turn cancer cells into potent, anti-cancer agents. Khalid Shah and his team have developed a new cancer-killing vaccine that can be used to treat existing tumors and prevent recurrences.

Read More
November 17, 2022
End Brain Cancer Mobile App Is Here!

To advance our mission of education and advocacy, we have developed a mobile app where you can find information and interact with the Brain Tumor Community. Download the app today.

Read More
October 27, 2022
20 Years of Improving Patient Access!

Meet the Mission Team behind our Programs that deliver our Mission and Advocacy efforts!

Read More
October 13, 2022
Making a Difference in Healthcare

Dellann Elliott Mydland, President & Board Chair, End Brain Cancer Initiative (EBCI), is a dynamic competitor due to her experience taking down brain tumors, brain cancer, and metastasized disease to the brain. Read her new article in The Corporate Magazine.

Read More
February 28, 2022
“Incisionless Surgery” Treatment Approach: Metabolic Targeting of GBM

This month’s CURE MAG Cover Tip brought to you by the End Brain Cancer Initiative,  and through our patient advocacy and disease education partnership with CURE, focuses on Glioblastoma Multiforme (GBM).

Read More
1 2 3


Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
corporate partners
upcoming events
About us
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram